GeneralConnection.com ➔ Dictionary
Dictionary Search

haemophilia b

Synonyms

Noun

1. hemophilia B

2. haemophilia B, Christmas disease, hemophilia, haemophilia, bleeder's disease

Usage
How durable is gene therapy for haemophilia B? - Nature
Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B | New England Journal of Medicine - The New England Journal of Medicine
Hemophilia B Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Novo Nordisk, Sanofi, Pfizer, Belief BioMed, Centessa Pharmaceuticals - StreetInsider
Clinical trial: Hemophilia B, (NCT06611436) - CRISPR Medicine - CRISPR Medicine
First subject dosed in Be Biopharma’s trial of haemophilia B therapy - Clinical Trials Arena
Gene therapy can help reduce joint bleeds in hemophilia B: New data - Hemophilia News Today
Explainer 2025 Why Is Hemophilia B Called Christmas Disease - Global Biotechnology Company
Hemophilia B gene therapy demonstrates long-term success - St. Jude Children's Research Hospital
EAHAD 2026: Nine-Year Outcomes of Gene Therapy - European Medical Journal
First German haemophilia B patient receives gene therapy HEMGENIX - PharmaTimes
Patients With Hemophilia Face Significant Burden Despite Treatment Type or Disease Severity - Docwire News
NICE Recommends First Subcutaneous Option for Haemophilia B - Medscape
Factor IX-Padua AAV gene therapy in hemophilia B: phases 1/2 and 3 trials - Nature
First NHS patient treated with CSL Behring’s haemophilia B gene therapy Hemgenix - PMLiVE
Fidanacogene Elaparvovec for Hemophilia B — A Multiyear Follow-up Study - The New England Journal of Medicine
Clinical trial: Hemophilia B, (NCT06379789) - CRISPR Medicine - CRISPR Medicine
Marstacimab Superior to On-Demand Prophylaxis for Hemophilia A, B, With Inhibitors - Docwire News
Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia B | New England Journal of Medicine - The New England Journal of Medicine
AAV Gene Therapy in Severe Hemophilia B - The New England Journal of Medicine
AAV Gene Therapy in Severe Hemophilia B - The New England Journal of Medicine
NICE recommends weekly injection for severe haemophilia B - The Pharmaceutical Journal
NMPA approves BBM and Takeda China’s haemophilia B therapy - Pharmaceutical Technology
Patient in Germany gets hemophilia B gene therapy Hemgenix - Hemophilia News Today
Five-year study confirms durable efficacy of etranacogene dezaparvovec - PharmaTimes
ASH: CSL proves efficacy of hemophilia B gene therapy Hemgenix holds up after 5 years - Fierce Pharma
First-in-human trial of hemophilia B treatment BE-101 starts dosing - Hemophilia News Today
One dose of gene therapy gives years of relief from blood disorder - Nature
HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors - Business Wire
FDA approves Alhemo® as once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B (HA/HB) without inhibitors - PR Newswire
HOPE-B: 5-Year Etranacogene Dezaparvovec Maintains Durable Efficacy and Safety in Hemophilia B, With Steven Pipe, MD - HCPLive
Alhemo Indication Expanded to Include Hemophilia A/B Without Inhibitors - MPR - Medical Professionals Reference
China Explores Weight-Based Pricing for First Domestic Hemophilia B Gene Therapy - NAVLIN DAILY
Haemophilia gene therapy patients thriving over a decade after treatment - University College London
Belief, Takeda’s home-grown haemophilia B gene therapy gains nod in China - FirstWord Pharma
(marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need - Business Wire
Pfizer’s Hympavzi significantly reduces bleeds in haemophilia patients - PMLiVE
Hemophilia B Gene Therapy Shows Promise as Long-Term Treatment - Docwire News
Systemic lupus erythematosus caused acquired hemophilia B without evidence of factor IX inhibitors - Wiley Online Library
Phase 3 Study Analysis Supports Concizumab Noninferiority to Prior Prophylaxis in Hemophilia A, HB, Without Inhibitors - Docwire News
Hull teenager first to be treated with new haemophilia drug - BBC
CSL Behring Signs Letter of Intent with pan-Canadian Pharmaceutical Alliance (pCPA) for Public Reimbursement of HEMGENIX® (etranacogene dezaparvovec), the First Gene Therapy for Hemophilia B - Yahoo Finance
Pfizer reports positive results from Phase III BASIS trial for haemophilia - Clinical Trials Arena
Spotlight on the ISTH Hemophilia Treatment Guidelines and Alternate Recommendations - Hematology Advisor
Novo Nordisk’s Alhemo approved by FDA for expanded haemophilia use - PMLiVE
Nonfactor Therapies for Hemophilia: Current Evidence, Clinical Relevance and Cost Considerations - Managed Healthcare Executive
FDA Expands Approval of Concizumab-mtci to Include Hemophilia A, B Without Inhibitor Use - Pharmacy Times
Six biotech companies leading the charge in hemophilia treatment - Labiotech.eu
UK Approves Marstacimab for Severe Haemophilia A or B - Medscape
First UK patient treated with CSL Behring’s gene therapy for Haemophilia B - Pharmafile
FDA Approves Concizumab as Daily Prophylaxis for Hemophilia A and B - Drug Topics
European Medicines Agency Issues Positive Opinion for Concizumab Label Update in Hemophilia - Docwire News
Why Hympavzi Secured English Funding For Hemophilia B But Not Hemophilia A - Citeline News & Insights
Pfizer Announces Positive Topline Phase 3 Results for HYMPAVZI™ in Hemophilia A or B with Inhibitors - Business Wire
FDA expands approvals for Novartis lipid drug, Novo haemophilia prophylatic - FirstWord Pharma
NHS treats first haemophilia B patient with gene therapy - Progress Educational Trust
Extended hemophilia half-life products aid care, but raise costs - Hemophilia News Today
Novo Nordisk’s Haemophilia B Study: Key Update on Nonacog Beta Pegol - TipRanks
Novo Nordisk’s Haemophilia B Study: Key Insights for Investors - TipRanks
Successful management with regular factor IX replacement during pregnancy in a hemophilia B carrier: A case report - Wiley
Veterinarian aims to bring hemophilia treatment to pet dogs - Veterinary Information Network®, Inc. - VIN
Expanding Alhemo to hemophilia without inhibitors recommended - Hemophilia News Today
Pfizer's weekly haemophilia drug backed for NHS use - pharmaphorum
Number of people with bleeding disorders worldwide in 2024, by condition - Statista
European regulatory authority adopts positive opinion for Novo Nordisk’s Alhemo® (concizumab), recommending label expansion to treat haemophilia A and B without inhibitors - Yahoo Finance
Gene therapy frees hemophilia patient from constant worry, needles - Harvard Gazette
Pfizer’s Hympavzi granted MHRA approval to treat haemophilia A and B - PMLiVE
Novo Nordisk to present phase 3 trials across hemophilia portfolio, reinforcing commitment to research in rare blood disorders, at ISTH 2025 - BioSpace
CSL’s haemophilia therapy shows durable five-year benefits in landmark trial results - BiotechDispatch
Get easily bruised? It may be due to haemophilia B - Healthshots
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B - The New England Journal of Medicine
Concizumab approved to prevent or reduce the frequency of bleeding episodes in people aged 12 years and older with haemophilia A or B with inhibitors - GOV.UK
Invited Medical Presentation Abstracts - 2025 - Haemophilia - Wiley Online Library
HHS pharmacy sets national benchmark: First-ever delivery of groundbreaking $4.5M Hemophilia B treatment - Hospital News
Gene therapy BBM-H901 approved for hemophilia B in China - Hemophilia News Today
First subcutaneous treatment for severe Haemophilia B recommended - National Health Executive
First NHS patient given world's most expensive drug that costs £2.6 million per dose - LADbible
Phase 1–2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B - The New England Journal of Medicine
Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec) Over Five Years - Mynewsdesk
First Hemophilia B Patient Receives Hemgenix in Austria - NAVLIN DAILY
Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B | New England Journal of Medicine - The New England Journal of Medicine
FDA clears Sanofi's siRNA as first rebalancing agent for all haemophilia patients - FirstWord Pharma
Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial - The Lancet
Germany will reimburse haemophilia gene therapy Hemgenix - pharmaphorum
As Pfizer backs out of hemophilia gene therapy space, CSL hopes Hemgenix is here to stay - Fierce Pharma
Sanofi’s Qfitlia approved by FDA as first haemophilia therapy for all patients - Pharmaceutical Technology
First gene therapy to treat haemophilia B - European Medicines Agency
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant | New England Journal of Medicine - The New England Journal of Medicine
CDC Hemophilia Mutation Projects (CHAMP and CHBMP) - Centers for Disease Control and Prevention | CDC (.gov)
First patient in Wales receives ground-breaking gene therapy treatment - Nation.Cymru
News and Expert Insights in Hemophilia Gene Therapy for Bleeding Disorders Awareness Month 2025 - CGTLive®
CSL Behring treats two patients with gene therapy for haemophilia B - Clinical Trials Arena
Hemophilia A, B in France has high clinical, economic burden for patients - Hemophilia News Today
With hemophilia B, a lifetime of worry eased with one infusion - Penn Today
Breaking ground in haemophilia B gene therapy: insights from the HOPE-B trial and beyond - The Lancet
Researchers welcome $3.5-million haemophilia gene therapy — but questions remain - Nature
Qfitlia approved by FDA to treat haemophilia A or B - Pharmafile
Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial - The Lancet
CRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice - Nature
Marstacimab approved to treat patients aged 12 years and above (weighing at least 35 kg) with haemophilia A or B - GOV.UK
Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system - Nature
Foreign Language Equivalents
Foreign Language Equivalents of 'haemophilia b'
Language Equivalent   Language Equivalent
French    Spanish
Misspellings - Typos
haemiphilia b,   haemoophilia b,   haeophilia b,   haemopilia b,   haaemophilia b,   haemophiliaa b,   hemophilia b,   haempohilia b,   haemohpilia b,   jaemophilia b,   haemophilai b,   haemophiliia b,   haemophiliab ,   haemophilia ,   haemophillia b,   haemophiia b,   haemmophilia b,   haemophilis b,   gaemophilia b,   haeemophilia b,   haempphilia b,   haemophila b,   hae,ophilia b,   hawmophilia b,   heamophilia b,   haemophilia n,   haemopjilia b,   haeomphilia b,   haemopphilia b,   haemophliia b,   haemophilia b,   haemophilia bb,   harmophilia b,   hameophilia b,   haemophilia v,   haemopgilia b,   haemophulia b,   haemopihlia b,   haemophiilia b,   aemophilia b,   haemophili b,   haemo[hilia b,   hamophilia b,   hsemophilia b,   haemophhilia b,   haemophiloa b,   haemophiliab,   haenophilia b,   haemoohilia b,   haemophikia b,   hhaemophilia b,   haemopholia b,   haemohilia b,   ahemophilia b,   haemphilia b,   haemophilua b,   haemophiila b,   haemophili ab,   haemophlia b,   haemophi;ia b
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z